期刊文献+

普伐他汀与阿司匹林联用对血脂和炎性标志物表达的影响 被引量:3

Effect of Combination Therapy with Pravastatin and Aspirin to Blood Lipid and Inflammatory Marker
暂未订购
导出
摘要 目的研究普伐他汀与阿司匹林联合应用对老年缺血性脑卒中患者血脂、血小板聚集率及炎性标志物表达的影响。方法经头颅CT或磁共振(MRI)诊断为脑梗死的患者68例,经2周洗脱期后随机分为普伐他汀与阿司匹林联合治疗组(普伐他汀10mg/d+阿司匹林50mg/d)和阿司匹林治疗组(阿司匹林50mg/d)各34例,随访9个月。于洗脱期后和随访结束时分别测定血脂、血小板聚集率及炎性标志物的表达。结果两组用药前后血小板聚集率均无显著变化(P>0.05);联合用药组随访结束时血清载脂蛋白A(apoA)明显升高,血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、载脂蛋白B(apoB)、apoB/apoA、C反应蛋白(CRP)、纤维蛋白原(Fbg)均较用药前明显降低(P<0.05或P<0.01);阿司匹林治疗组血脂各项指标、CRP、Fbg用药前后均无显著变化(P>0.05)。结论提示普伐他汀与阿司匹林联合应用对老年缺血性脑卒中患者具有显著的调脂和抑制炎性反应的作用,为阻断动脉粥样硬化的进展、预防再梗死的发生提供了依据。 ObjectiveTo evaluate the effect of combination therapy with pravastatin and aspirin on blood lipid,platelet aggregation ratio and inflammatory marker for cerbral infarction in the elderly.Methods After two weeks of eluting, a total of 68 aged patients with cerbral infarction were randomly assigned to receive a combination of 10 mg pravastatin +50 mg aspirin per day (group P, n=34) or 50 mg aspirin per day (group A, n=34) for 9 months. Lipid profiles,platelet aggregation ratio, C reaction protein(CRP) and fibrinogen (Fbg) were tested before and after the study.ResultsThe platelet aggregation ratio had no siganificant change in both groups after the study (P>(0.05).) In group P, serum apo A was siganificant increased while TC, LDL-C, apo B, apo B/apo A, CRP and Fbg were all siganificant decreased after treatment(P<0.05 or P<0.01). There was no significant change of the lipid profiles, CRP and Fbg after the study in group A (P>0.05).ConclusionThe combination therapy of pravastatin and aspirin has safe and significant effect to adjust blood lipid and inhibit inflammatory reaction and provides evidence of preventing the progression of artherosclerosis and restroke in the elderly.
出处 《上海第二医科大学学报》 CSCD 北大核心 2005年第7期705-707,共3页 Acta Universitatis Medicinalis Secondae Shanghai
基金 卫生部干部保健司基金(沪C203)资助项目.
关键词 普伐他汀 阿司匹林 血脂 血小板聚集率 炎性标志物 <Keyword>pravastatin aspirin blood lipid platelet aggregation ratio inflammatory marker
  • 相关文献

参考文献11

  • 1Martin PV, Vodillo J, Diaz J, et al. Fibrinogen and fibrinolysis in blood and in the arterial wall: its role in advanced atherosclerotic disease[J]. Cardiovasc Surg,1998, 6(5): 457-562.
  • 2Morrisett JD. The role of lipoprotein(a) in atherosclerosis[J]. Curr Atheroscler Rep,2000, 2(3): 243-250.
  • 3Horimoto M, Hasegawa A, Takenaka T. Long-term administration of pravastatin reduces serum lipoprotein(a) levels[J]. Int J clin Pharmacol Ther,2003, 41(11): 524-530.
  • 4戴云,李进.血小板活化反应的信号传递机制[J].解剖科学进展,1995,1(2):149-161. 被引量:6
  • 5Quan Seng L, Levenson J, Megnien JL, et al. Platelet cytosolic Ca2+ and membrane dynamics in patients with primary hypercholestero lemia: effects of pravastatin[J]. Arterioscler Thromb Vasc Biol,1995, 15: 759-764.
  • 6Pasceri V, Chang J, Willerson JT, et al. Modulation of C-reactive protein mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs[J]. Circulation,2001, 103(21): 2531-2534.
  • 7Zwaka TP, Hornbach V, Torzewski J. C-reactive protein mediated low density lipoprotein uptake by macrophages:implications for atherosclerosis[J]. Circulation, 2001, 103(9): 1194-1197.
  • 8Yeh ET, Anderson HV, Pasceri V, et al. C-reactive protein: lin-king inflammation to cardiovascular complication[J]. Circulation, 2001, 104(9): 974-975.
  • 9Steven M, Patrick J ,Louis C,et al. Effect of atorvastatin and pravastatin on serum C-reactive protein[J].Am Heart J,2003,145(2): E8.
  • 10Kannel WB. Fibrinogen and the risk of cardiovascular disease, the Framingham study[J]. American Medical Association, 1987, 258(9): 1183-1186.

共引文献5

同被引文献42

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部